MINI REVIEW article
Front. Microbiol.
Sec. Phage Biology
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1621103
This article is part of the Research TopicHarnessing Bacteriophages and Phage-Engineered Products for Antibacterial and Anticancer Therapies: Challenges and OpportunitiesView all 6 articles
Phage Therapy for Environmental Biotechnology Applications
Provisionally accepted- 1Cranfield University, Cranfield, United Kingdom
- 2College of Science, Engineering and Technology, University of South Africa, Institute for Nanotechnology and Water Sustainability, Johannesberg, South Africa
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Environmental compartments, from soils and crop rhizospheres, to bio-reactors and municipal water networks have emerged as dynamic hot-spots for antimicrobial-resistance evolution and dissemination. Bacteriophages offer a precision, self-amplifying alternative to conventional biocides, yet their environmental deployment, intellectual-property space and commercial readiness remain only partially charted. Here, we critically synthesise the past decade of progress in phage-based interventions across three sectors: (i) soil remediation and crop-protection interfaces, where multi-phage cocktails suppress wilt-and blight-causing pathogens while preserving beneficial microbiota; (ii) biofuel and petroenergy infrastructures, in which lytic phages mitigate the microbiologically influenced corrosion and contaminated fermentations, restoring ethanol yields; and (iii) natural and engineered water systems, where phages show promise in treating recalcitrant biofilms, algal blooms and selectively ablate World Health Organisation-priority pathogens. Meta-analysis of the World Intellectual Property Organization database reveals rapidly rising but geographically skewed patent activity, with China and the United States accounting for >61 % of reviewed filings, and a gap between laboratory proof-of-concepts and marketed products. We identify bottlenecks, including lack of good manufacturing practice at scale, fragmented regulatory frameworks, and the evolutionary balance between single-phage precision and cocktail breadth. A roadmap is suggested that couples high-throughput phage discovery, synthetic tailoring and adaptive approval pathways. Together, these advances position environmental phage therapy to become a cornerstone of the One-Health response to increasing levels of microbial resistance.
Keywords: phage therapy, Patent landscape, Soil-vegetable system, Biofuel system, engineered water system Font: Italic Formatted: Font: Italic Formatted: Font: Italic Formatted: Font: Italic Formatted: Font: Italic Formatted: Font: Italic Formatted: Font: Italic Formatted: Font: Italic
Received: 30 Apr 2025; Accepted: 18 Aug 2025.
Copyright: © 2025 Singh, Samson and Hassard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Suniti Singh, Cranfield University, Cranfield, United Kingdom
Francis Hassard, Cranfield University, Cranfield, United Kingdom
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.